Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for third-line or later treatment of advanced epithelial ovarian cancer
ChiCTR1900024312Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in epithelial ovarian cancer (EOC), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Progression-free survival. Started Jul 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR1900024312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024312.